Company Overview
Pharmaceutical development invariant Natural Killer T (iNKT) cell platform for cancer treatment and its oral spray delivery technology to treat cancer and conditions that affect the central nervous system.
| Website | www.arovella.com |
|---|---|
| Head Office | Osborne Park WA |
| Registry | Automic Pty Ltd |
| CEO | Michael Baker |
| Chair Person | Elizabeth Stoner |
| GICS Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Sub Industry | Pharmaceuticals |
| Sector | Health Care |
| Market Cap | $18 m |
|---|---|
| Shares on Issue | 672 m |
| Status | Trading |
| Last Price | |
| Change | |
| 52 Week H/L | |
| VWAP | |
| Bid/Ask |
Directors and Management
No data to display.
Top 20 Shareholders
No data to display.
Director Transactions
No data to display.